Chris’ note: Tonight’s the night… At 8 p.m. ET, our tech expert, Jeff Brown, is sharing big news. It’s about a discovery he’s made in the biotech sector. If he’s right, his No. 1 stock pick could see up to 1,000% gains – in a single day.
Tiny biotech companies have soared 900%… 1,130%… even 1,288% on special days. Now, Jeff believes it’s going to happen again. It has to do with a company that’s curing one of the world’s most debilitating diseases. And when you find out what the disease is… Jeff’s claim will make a lot more sense.
So make sure you’re signed up for Jeff’s biotech masterclass here. Then read on below for more from him on the revolutionary potential of this breakthrough medical tech.
Grace Wilsey couldn’t cry…
As a baby, she would lie limp in her parents’ arms, staring blankly into the distance.
Her seizures wouldn’t stop. Medical tests showed signs of liver damage.
This was all before her second birthday.
Grace’s parents were beside themselves, as any parent would be. They traveled the country visiting specialists. They ran a battery of tests. But no one could diagnose Grace’s condition.
“We’ve probably seen over 100 doctors,” Grace’s father said in 2014, when her symptoms were discovered.
None of them could provide an explanation.
Then, when their daughter turned two years old, the Wilseys tried something else.
They had Grace’s entire genome sequenced.
Our genome is our complete set of DNA.
Genome sequencing is the process of figuring out our complete DNA sequence. Think of it like a “blueprint” of our genetic material.
What these genetic tests showed about Grace was astounding…
She had a condition known as NGLY1 deficiency. In short, the little girl’s NGLY1 gene was mutated. She had a “typo” in her genome. This is what was making her sick.
Grace’s disorder was so poorly understood, doctors had diagnosed only six people with it.
Grace’s story is just one of millions. More than 300 million people suffer from a rare genetic disease. Many of them often live their lives undiagnosed… and their suffering remains a mystery.
But there’s hope on the horizon.
The method the Wilsey family used, genome sequencing, has plummeted in cost. The speed of the sequencing technology has grown exponentially.
And thanks to breakthroughs in genetic-editing technology – what I call the “God Key” because of its power to alter our bodies – we’re on the verge of a complete transformation in medical care.
Now that doctors understand diseases’ genetic origins, they can develop specific genetic therapies to deal with unusual genetic mutations.
They can now permanently cure previously untreatable diseases. And living to 100 and beyond will be the norm, not the exception.
We’ll also experience a better quality of life along the way.
Imagine hiking the Grand Canyon for your 100th birthday. Or playing a round of golf at 110.
This is the future I see. And it presents one of the best investment opportunities of our lifetimes.
Today, most of us wait until symptoms show up before seeking treatment for an illness.
If we get sick, we typically use a “one-size-fits-all” approach to treat the disease. And it addresses only our symptoms, not the underlying cause of our illness.
Scientists haven’t had the tools necessary to cure the diseases permanently. So our healthcare strategies have been mostly reactionary.
But that’s about to change…
As I’ve been telling my readers, we’re witnessing the rise of personalized medicine.
Thanks to genetic sequencing, we can now spot diseases years or even decades before symptoms present themselves.
And with genetic-editing technology, we can literally edit disease out of our body, curing us permanently.
Our healthcare will also be personalized based on our unique genetic makeup.
As a result, human beings will live well past a century. And we’ll be healthier, and more active, in our golden years.
This tech isn’t years away. It’s available right now. And it’s becoming more affordable…
In 2001, Dr. Craig Venter and his team at Celera Genomics in California completed the first full human genome sequencing.
But as recently as late 2019, the price tag to sequence a full genome plunged below $1,000. That’s an exponential decline.
It’s all in this next chart.
The cost to sequence a human genome has fallen at an even faster exponential rate than Moore’s Law. Moore’s Law is the observation that the power of microchips has doubled roughly every two years. It’s the gold standard for measuring exponential growth in technology.
For a technology to outpace Moore’s Law like this is incredible. And the cost to sequence an entire genome is continuing to fall.
Earlier this year, Chinese genetic-sequencing company BGI Group announced it could deliver full genome sequencing for a mere $100.
This price point changes the game for health insurance companies. Insurance providers can cover full genome sequencing for all patients. We’re already seeing this.
Back in 2017, UnitedHealthcare began covering “whole exome [a part of the genome] sequencing for patients where clinical presentation is nonspecific and does not fit a well-defined syndrome.”
In other words, if a physician knows something is wrong with you, but can’t figure out what it is, UnitedHealthcare pays for genetic sequencing.
In late 2019, health insurer Cigna added direct-to-customer genetic screenings to its network. This gave 16 million people easy access to genetic sequencing.
And in March, Blue Shield of California, another health insurer, began covering rapid and ultra-rapid whole-genome sequencing for critically ill children.
That’s right: We can even protect babies with this technology.
Imagine the consequences …
Doctors will no longer have to make educated guesses when you’re sick. Instead, they’ll run genetic tests and figure out with certainty whether your illness is the result of a genetic condition.
That means you’ll no longer have to suffer through a trial-and-error process, like the Wilseys.
We’ll see healthcare costs plummet. Doctors won’t have to run extensive tests to search for the problem. And you won’t have to try different drugs, testing what works.
Whole-genome sequencing will provide the answers.
We should all celebrate this technology. It will help us live longer, healthier lives.
And for us as investors, it marks a once-in-a-generation opportunity.
The precision medicine megatrend is at the start of a yearslong bull market.
The returns we’ll see from quality biotech companies will create lasting, multigenerational wealth.
For you as an investor, the time to get exposure to the precision medicine trend is now. Right now.
There’s one stock in particular I don’t want you to miss out on. The small-cap stock could soar as much as 1,000% in a single day when it makes a critical announcement about the clinical trials it has underway.
That’s why I’m hosting a special event TONIGHT at 8 p.m. ET. I’m calling it The Cure Event.
I’ll share all the details with readers who attend. Go right here to reserve your spot for free.
I hope to see you there.
Editor, The Bleeding Edge